Cyproheptadine and Chlorpromazine Effects on Spasticity

Spinal Cord Injuries Clinical Trial

Official title:

Phase 3 Study of Cyproheptadine and Chlorpromazine Effects on Spasticity After Spinal Cord Injury

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01509885
• Other study ID #: Pro00020682
• Status: Completed
• Phase: N/A
• First received: January 10, 2012
• Last updated: November 16, 2012
• Start date: July 2010
• Est. completion date: November 2012

Study information

• Verified date: November 2012
• Source: University of Alberta
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health CanadaCanada: Ethics Review Committee
• Study type: Observational

Clinical Trial Summary

The main goal of this research is to understand the neuronal mechanisms that mediate the development of spasticity and motor dysfunction after spinal cord injury. The investigators examine how neurons and neuronal circuits in an injured nervous system adapt to produce the uncontrolled and unwanted muscle contractions that affect the majority (80%) of patients with spinal cord injury. One of the neurons that the investigators study is the motoneuron that excites the muscles of the limbs to produce movement. Previously, the investigators have shown that after spinal cord injury, the excessive and uncontrolled activity of motoneurons during muscle spasms is mediated, in large part, by the activation of calcium currents in the human motoneuron. In human patients the investigators have used recordings from single muscle fibres to estimate the contribution of these calcium currents in activating the motoneuron during muscle spasms. In this proposal, the investigators study why motoneurons recover these calcium currents and self-sustained activity after chronic spinal cord injury. Because the calcium currents require the presence of the monoamine serotonin (5HT) to activate, and this monoamine is greatly reduced after injury, the investigators examine if the calcium currents recover because the 5HT receptors become spontaneously active without the need for 5HT to bind to the receptor, which the investigators hypothesize to be one of the causes of spasticity after spinal cord injury. This research will pave the way to develop new pharmacological and rehabilitative therapies to both control spasticity after spinal cord injury and augment residual motor movements.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: November 2012
• Est. primary completion date: November 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 17 Years and older

Eligibility

Inclusion Criteria:

Patients must have suffered a trauma to the spinal cord at least 6 months ago or longer. In addition, subjects must exhibit some degree of spasticity as determined by having an Ashworth Spasticity Score, as assessed by a physical therapist, greater than 1.

Exclusion Criteria:

• If patients have damage to the nervous system other than to the spinal cord

• Pregnant women

• Elderly Patients and debilitated patients

• Alcoholic Patients

• Patients with:

• Known or suspected allergy to the medication or its ingredients

• Cardiovascular disease

• Hypotension

• Coronary artery disease

• Reduced liver or kidney function

• Comatose or depressed states due to CNS depressants

• Blood dyscrasias

• Bone marrow depression

• History of seizures

• Respiratory problems

• Hypocalcemia

• Monoamine oxidase inhibitor therapy

• Angle-closure glaucoma

• Stenosing peptic ulcer

• Symptomatic prostatic hypertrophy

• Bladder neck obstruction

• Pyloroduodenal obstruction

• History of bronchial asthma

• Increased intraocular pressure

• Hyperthyroidism

• Cardiovascular disease

• Hypertension

• Patients taking:

• Amphetamines

• Antihistamines-second generation

• Anticonvulsants

• Anticholinergics

• CNS depressants

• Antidepressants

• Hypotensive agents

• Levodopa

• Lithium

Study Design

N/A

Related Conditions & MeSH terms

• Muscle Spasticity
• Spinal Cord Injuries

Locations

Country	Name	City	State
Canada	University of Alberta	Edmonton	Alberta

Sponsors (1)

Lead Sponsor	Collaborator
University of Alberta

Country where clinical trial is conducted

Canada, 

References & Publications (1)

Murray KC, Nakae A, Stephens MJ, Rank M, D'Amico J, Harvey PJ, Li X, Harris RL, Ballou EW, Anelli R, Heckman CJ, Mashimo T, Vavrek R, Sanelli L, Gorassini MA, Bennett DJ, Fouad K. Recovery of motoneuron and locomotor function after spinal cord injury depe — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cutaneomuscular Reflex Responses	Tibialis anterior reflex responses evoked by stimulation of the medial arch of the foot will be measured before and after drug administration.	Change after drug intake at baseline, 30minutes, 60minutes, 90minutes and 120minutes	No
Primary	Paired motor unit recordings	We obtain paired motor unit recordings to determine changes in neuronal excitability after drug intake in incomplete spinal-cord injured subjects only.	Change at baseline and 30, 60, 90 and 120min after drug intake	No
Secondary	Blood pressure and Heart rate	We measure blood pressure and heart rate to determine the safety of the drug during the experiment and whether we can continue safely.	Change at baseline and 30, 60, 90, 120 minutes after drug intake	Yes

External Links

•   Link